A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

Published:2018-07-13 Issue:4 Volume:104 Page:655-663
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Bartko Johann¹²,Schoergenhofer Christian¹^ORCID,Schwameis Michael¹,Firbas Christa¹,Beliveau Martin³,Chang Colin³,Marier Jean-Francois³,Nix Darrell⁴,Gilbert James C.⁵,Panicker Sandip⁶,Jilma Bernd¹

Affiliation:

1. Department of Clinical Pharmacology; Medical University of Vienna; Vienna Austria

2. Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling; 1st Medical Department Hanusch Hospital; Vienna Austria

3. Certara Strategic Consulting; Montreal Canada

4. Drug Development Consulting

5. True North Therapeutics Inc.; South San Francisco California USA (a Bioverativ company)

6. Bioverativ Therapeutics Inc.; South San Francisco California USA

Funder

Bioverativ Therapeutics Inc.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.1111/fullpdf

Reference19 articles.

1. TNT009, a classical complement pathway specific inhibitor, prevents complement dependent hemolysis induced by cold agglutinin disease patient autoantibodies;Shi;Blood,2013

2. Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity;Colonna;Clin. Immunol.,2016

3. Combined integrated protocol/basket trial design for a first-in-human trial;Derhaschnig;Orphanet J. Rare Dis.,2016

4. Lyse or not to lyse: clinical significance of red blood cell autoantibodies;Meulenbroek;Blood Rev.,2015

5. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies;Reynaud;Autoimmun. Rev.,2015

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose riliprubart, an anti-C1s humanized monoclonal antibody in East-Asian adults: results from a Phase 1, randomized, open-label trial;Expert Opinion on Investigational Drugs;2024-08-22

2. Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B;eClinicalMedicine;2024-08

3. The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms;Expert Review of Hematology;2024-06-28

4. Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy;Current Oncology Reports;2024-06-14

5. Sutimlimab suppresses SARS-CoV-2 mRNA vaccine-induced hemolytic crisis in a patient with cold agglutinin disease;Journal of Clinical and Experimental Hematopathology;2023-12-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3